Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome

Journal of the American Society of Nephrology

Volumn 26, Issue 2, 2015, Pages 468-475

  Blanchard, Anne ^a,b,c   Vargas Poussou, Rosa ^b,c   Vallet, Marion ^d   Caumont Prim, Aurore ^b,c   Allard, Julien ^e   Desport, Estelle ^f   Dubourg, Laurence ^g   Monge, Matthieu ^b   Bergerot, Damien ^c   Baron, Stéphanie ^a,b   Essig, Marie ^e   Bridoux, Frank ^f   Tack, Ivan ^d   Azizi, Michel ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSERM   (France)

^d CHU RANGUEIL   (France)

^e DUPUYTREN UNIVERSITY HOSPITAL   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMILORIDE; CALCIUM; CREATININE; EPLERENONE; INDOMETACIN; MAGNESIUM; OMEPRAZOLE; POTASSIUM; RENIN; SODIUM; SPIRONOLACTONE;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CALCIUM URINE LEVEL; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; GITELMAN SYNDROME; GLOMERULUS FILTRATION RATE; HEART PALPITATION; HEART RATE; HEARTBURN; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; LOW DRUG DOSE; MAGNESIUM BLOOD LEVEL; MAGNESIUM EXCRETION; MAGNESIUM URINE LEVEL; MALE; MINERAL SUPPLEMENTATION; OPEN STUDY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SLOW RELEASE FORMULATION; SODIUM BLOOD LEVEL; SODIUM DEPLETION; SODIUM EXCRETION; SODIUM URINE LEVEL; STOMACH IRRITATION; SUPPLEMENTATION; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; BLOOD PRESSURE; COMPLICATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AMILORIDE; BLOOD PRESSURE; BODY WEIGHT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GITELMAN SYNDROME; GLOMERULAR FILTRATION RATE; HEART RATE; HUMANS; HYPOKALEMIA; INDOMETHACIN; MALE; MIDDLE AGED; POTASSIUM; RENIN; SPIRONOLACTONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923882104     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014030293     Document Type: Article

References (41)

1. Knoers NV, Levtchenko EN: Gitelman syndrome. Orphanet J Rare Dis 3: 22, 2008
2. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ, Gitleman HJ, Lifton RP: Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl co-transporter. Nat Genet 12: 24-30, 1996
3. Malafronte C, Borsa N, Tedeschi S, Syrèn ML, Stucchi S, Bianchetti MG, Achilli F, Bettinelli A: Cardiac arrhythmias due to severe hypokalemia in a patient with classic Bartter disease. Pediatr Nephrol 19: 1413-1415, 2004
4. Ahmed S, Qayyum M, Farooq F: Quadriparesis in an adult - Gitelman syndrome. J Pak Med Assoc 61: 182-184, 2011
5. Scognamiglio R, Negut C, Calò LA: Aborted sudden cardiac death in two patients with Bartter's/Gitelman's syndromes. Clin Nephrol 67: 193-197, 2007
6. Slyper AH: Growth, growth hormone testing and response to growth hormone treatment in Gitelman syndrome. J Pediatr Endocrinol Metab 20: 257-259, 2007
7. Pachulski RT, Lopez F, Sharaf R: Gitelman's not-so-benign syndrome. N Engl J Med 353: 850-851, 2005
8. Park PG Jr, Karet Frankl FE: Gitelman syndrome. BMJ 344: e3590-851, 2012
9. McMahon FG, Ryan JR, Akdamar K, Ertan A: Upper gastrointestinal lesions after potassiumchloride supplements: A controlled clinical trial. Lancet 2: 1059-1061, 1982
10. Peters M, Jeck N, Reinalter S, Leonhardt A, Tönshoff B, Klaus G G, Konrad M, Seyberth HW: Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 112: 183-190, 2002
11. Monnens L, Bindels R, Grünfeld JP: Gitelman syndrome comes of age. Nephrol Dial Transplant 13: 1617-1619, 1998
12. Ito Y, Yoshida M, Nakayama M, Tsutaya S, Ogawa K, Maeda H, Miyata M, Oiso Y: Eplerenone improved hypokalemia in a patient with Gitelman's syndrome. Intern Med 51: 83-86, 2012
13. Morton A: Eplerenone in the treatment of Gitelman's syndrome. Intern Med J 38: 377, 2008
14. Morton A, Panitz B, Bush A: Eplerenone for gitelman syndrome in pregnancy. Nephrology (Carlton) 16: 349, 2011
15. Liaw LC, Banerjee K, Coulthard MG: Dose related growth response to indometacin in Gitelman syndrome. Arch Dis Child 81: 508-510, 1999
16. Colussi G, Rombolà G, De Ferrari ME, Macaluso M, Minetti L: Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. Am J Nephrol 14: 127-135, 1994
17. Murdoch DL, Forrest G, Davies DL, McInnes GT: A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects. Br JClin Pharmacol 35: 373-378, 1993
18. Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15: 709-716, 2002
19. Brown NJ: Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9: 459-469, 2013
20. Matzdorf C, Kurtz A, Höcherl K: COX-2 activity determines the level of renin expression but is dispensable for acute upregulation of renin expression in rat kidneys. Am J Physiol Renal Physiol 292: F1782-F1790, 2007
21. Seyberth HW, Schlingmann KP: Bartter- and Gitelman-like syndromes: Salt-losing tubulopathies with loop or DCT defects. Pediatr Nephrol 26: 1789-1802, 2011
22. Kirchner KA: Indomethacin antagonizes furosemide's intratubular effects during loop segment microperfusion. J Pharmacol Exp Ther 243: 881-886, 1987
23. Kirchner KA, Brandon S, Mueller RA, Smith MJ, Bower JD: Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. Kidney Int 31: 1097-1103, 1987
24. Kammerl MC, Nüsing RM, Richthammer W, Krämer BK, Kurtz A: Inhibition of COX-2 counteracts the effects of diuretics in rats. Kidney Int 60: 1684-1691, 2001
25. Breyer MD, Harris RC: Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens 10: 89-98, 2001
26. Stichtenoth DO, Frölich JC: COX-2 and the kidneys. Curr Pharm Des 6: 1737-1753, 2000
27. Palmer BF: Renal complications associated with use of nonsteroidal anti-inflammatory agents. J Investig Med 43: 516-533, 1995
28. Passmore AP, Copeland S, Johnston GD: The effects of ibuprofen and indomethacin on renal function in the presence and absence of frusemide in healthy volunteers on a restricted sodium diet. Br J Clin Pharmacol 29: 311-319, 1990
29. Sandhu GK, Heyneman CA: Nephrotoxic potential of selective cyclo-oxygenase-2 inhibitors. Ann Pharmacother 38: 700-704, 2004
30. Schlondorff D: Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 44: 643-653, 1993
31. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, Shekelle P: Ametaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 29: 804-812, 2002
32. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C; Coxib and traditional NSAID Trialists' (CNT) Collaboration: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs:Meta-analyses of individual participant data from randomised trials. Lancet 382: 769-779, 2013
33. García Rodríguez LA, Tacconelli S, Patrignani P: Role of dose potency in the prediction of risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52: 1628-1636, 2008
34. Famularo G, Gasbarrone L, Minisola G: Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf 12: 709-716, 2013
35. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, Laurent S, Menard J, Plouin PF: Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: A prospective, randomized, open blinded endpoint study. J Hypertens 30: 1656-1664, 2012
36. Leplège A, Ecosse E, Verdier A, Perneger TV: The French SF-36 Health Survey: Translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 51: 1013-1023, 1998
37. Blanchard A, Azizi M, Peyrard S, Stern N, Alhenc-Gelas F, Houillier P, Jeunemaitre X: Partial human genetic deficiency in tissue kallikrein activity and renal calciumhandling. Clin J Am Soc Nephrol 2: 320-325, 2007
38. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G: Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100, 2005
39. Nguyen G, Blanchard A, Curis E, Bergerot D, Chambon Y, Hirose T, Caumont-Prim A, Tabard SB, Baron S, Frank M, Totsune K, Azizi M: Plasma soluble (pro)renin receptor is independent of plasma renin, prorenin, and aldosterone concentrations but is affected by ethnicity. Hypertension 63: 297-302, 2014
40. Senn S: Cross-Over Trials in Clinical Research, Chichester, United Kingdom, Wiley, 2000
41. Aickin M, Gensler H: Adjusting for multiple testing when reporting research results: The Bonferroni vs Holmmethods. Am J Public Health 86: 726-728, 1996